By their own admission they claim their study is not designed to look at the same though they feel it improves survival. remeber their is no obective data that INCY has provided at this point so not so different from YMI.

FORBES: Two-Minute Take: The Case For Exelixis And Incyte

In the fiercely competitive and risk-laden life sciences industry, what the little-known YM Biosciences (YMI) has achieved in just 12 months caught the attention of a big crowd of investors, analysts, and scientists at the June 3rd meeting of the highly respected American Society for Clinical Oncology (ASCO).

FORBES: YM Biosicences: Its Data at ASCO On Drug for Bone Marrow Disorders Catapults Its Stock